Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zika Vaccine Timeline: Will It Be Too Little Too Late?

Executive Summary

Following the Zika outbreak in Latin America in late 2015, a number of pharmaceutical companies have stepped up their vaccine research efforts against a virus that has now been scientifically determined as the cause of microcephaly and other severe brain defects in babies. But will a product be able to reach the market soon enough to have an impact on the current outbreak?

You may also be interested in...



Ports, Prosthetics Take Blame In Partial Hold For Aduro’s Immunotherapy Trials

Aduro hopes for a relatively quick resolution to a clinical hold for its LADD cancer vaccine studies instituted by the FDA based on listeria detected around indwelling ports in two patients.

From One To Seven In 12 Days: ZIKV Vaccine Candidates Speed Into Labs

When Scrip first wrote about Zika virus (ZIKV) less than two weeks ago there was no record of any clinical development ongoing for a treatment or vaccine against the mosquito-transmitted disease, let alone any available therapies.

Zika Virus Vaccine Hunt Begins Following 4,000 Brazilian Birth Defects

The pharma industry's (and the media's) interest in Ebola has begun to wane as more affected African countries secure disease-free status from the World Health Organization, but another tropical condition has started to capture headlines – Zika virus (ZIKV), a mosquito transferred disease reportedly responsible for approximately 4,000 child birth defects since Oct. 2015.

Topics

Related Companies

UsernamePublicRestriction

Register

SC065233

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel